Skip to main content

Protocol M

Type:
Incidence / prospective cohort
Study Status:
Completed
Enrollment Status:
Closed
Countries:
Kenya
Partners:
Kenya AIDS Vaccine Initiative-Kangemi (KAVI-Kangemi), Nairobi, Kenya; Kenya AIDS Vaccine Initiative-Kenyatta National Hospital (KAVI-KNH), Nairobi, Kenya

 
Study Summary:
 
To assess vaccine-induced mucosal HIV-1-specific immune responses in volunteers concurrently enrolled in HIV preventive vaccine trials

Secondary Objectives:
To determine volunteers’ acceptance of mucosal sampling methodsTo help establish the reproducibility and validity of methods of assessing vaccine-induced mucosal HIV-1-specific immune responses.
To compare vaccine-induced systemic HIV-1-specific immune responses with HIV-1-specific immune responses at mucosal surfaces